Overview Dividends

(FRE) Fresenius SE & Co. KGaA - Ratings and Ratios

Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE0005785604

Infusion, Nutrition, Disposables, Pumps, Devices

Health Care Facilities
Market Cap in USD: 31,696m

IPO / Inception:
Return 12m vs S&P 500: 27.5%

EPS (Earnings per Share)

EPS CAGR: -3.58%
EPS Trend: 20.0%

Last SUE: 0.39
Qual. Beats: 0

Revenue

Rev. CAGR: -14.72%
Rev. Trend: -84.9%

Last SUE: -0.10
Qual. Beats: 0

Dividends

Dividend Yield	2.05%
Yield on Cost 5y	2.87%
Yield CAGR 5y	-18.15%
Payout Consistency	81.3%
Payout Ratio	30.2%

Risk via 5d forecast
Volatility	21.5%
Value at Risk 5%th	32.7%
Relative Tail Risk	-7.47%

Reward TTM
Sharpe Ratio	1.75
Alpha	44.50
CAGR/Max DD	1.00

Character TTM
Hurst Exponent	0.428
Beta	0.029
Beta Downside	0.037

Drawdowns 3y
Max DD	22.08%
Mean DD	6.48%
Median DD	4.79%

Description: FRE Fresenius SE & Co. KGaA December 17, 2025

Fresenius SE & Co. KGaA (XETRA:FRE) is a German-based integrated health-care group that serves chronically ill patients through two main divisions: Fresenius Kabi, which supplies critical-care and nutrition products (e.g., parenteral nutrition, infusion pumps, apheresis and cell-therapy devices), and Fresenius Helios, which operates a network of hospitals and nursing facilities. The firm, originally founded in 1912 and renamed in 2011, is headquartered in Bad Homburg vor der Höhe.

Key performance indicators that analysts watch include: (1) **Helios EBITDA margin**, historically around 8-9 % and sensitive to occupancy rates and payer mix; (2) **Kabi’s organic sales growth**, typically 3-5 % YoY, driven by aging populations and increasing demand for home-infusion therapies; and (3) **Free cash flow conversion**, which has averaged 70-80 % of operating cash flow, underpinning the company’s dividend policy. Macro-level drivers are demographic aging in Europe, rising chronic disease prevalence, and the shift toward outpatient and home-based care, which together expand both product and service addressable markets.

For a deeper, data-rich assessment of FRE’s valuation and risk profile, consider exploring the analytical dashboards on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (1.14b TTM) > 0 and > 6% of Revenue (6% = 1.34b TTM)

FCFTA 0.02 (>2.0%) and ΔFCFTA -3.99pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 11.17% (prev 13.28%; Δ -2.11pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.06 (>3.0%) and CFO 2.64b > Net Income 1.14b (YES >=105%, WARN >=100%)

Net Debt (11.53b) to EBITDA (2.57b) ratio: 4.48 <= 3.0 (WARN <= 3.5)

Current Ratio 1.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (563.2m) change vs 12m ago 0.21% (target <= -2.0% for YES)

Gross Margin 24.99% (prev 23.82%; Δ 1.17pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 52.69% (prev 52.42%; Δ 0.27pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 6.52 (EBITDA TTM 2.57b / Interest Expense TTM 263.0m) >= 6 (WARN >= 3)

Altman Z'' 2.93

(A) 0.06 = (Total Current Assets 12.06b - Total Current Liabilities 9.56b) / Total Assets 42.46b

(B) 0.44 = Retained Earnings (Balance) 18.60b / Total Assets 42.46b

(D) 0.80 = Book Value of Equity 19.16b / Total Liabilities 23.84b

Total Rating: 2.93 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 46.66

1. Piotroski 5.0pt

2. FCF Yield 1.96%

3. FCF Margin 3.34%

4. Debt/Equity 0.73

5. Debt/Ebitda 4.48

6. ROIC - WACC (= -0.03)%

7. RoE 6.03%

8. Rev. Trend -84.91%

9. EPS Trend 20.02%

What is the price of FRE shares?

As of December 26, 2025, the stock is trading at EUR 48.76 with a total of 390,299 shares traded.
Over the past week, the price has changed by +1.75%, over one month by +2.31%, over three months by +5.63% and over the past year by +49.09%.

Is FRE a buy, sell or hold?

Fresenius SE & Co. KGaA has no consensus analysts rating.

What are the forecasts/targets for the FRE price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	54.3	11.4%
Analysts Target Price	-	-
ValueRay Target Price	55.9	14.6%

FRE Fundamental Data Overview December 18, 2025

Market Cap USD = 31.70b (26.91b EUR * 1.1778 EUR.USD)
Market Cap EUR = 26.91b (26.91b EUR * 1.0 EUR.EUR)
P/E Trailing = 23.3073
P/E Forward = 13.089
P/S = 1.199
P/B = 1.4346
P/EG = 0.3848
Beta = 0.921
Revenue TTM = 22.35b EUR
EBIT TTM = 1.72b EUR
EBITDA TTM = 2.57b EUR
Long Term Debt = 9.53b EUR (from longTermDebt, last quarter)
Short Term Debt = 470.0m EUR (from shortTermDebt, last quarter)
Debt = 13.58b EUR (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 11.53b EUR (from netDebt column, last fiscal year)
Enterprise Value = 38.12b EUR (26.91b + Debt 13.58b - CCE 2.36b)
Interest Coverage Ratio = 6.52 (Ebit TTM 1.72b / Interest Expense TTM 263.0m)
FCF Yield = 1.96% (FCF TTM 746.0m / Enterprise Value 38.12b)
FCF Margin = 3.34% (FCF TTM 746.0m / Revenue TTM 22.35b)
Net Margin = 5.11% (Net Income TTM 1.14b / Revenue TTM 22.35b)
Gross Margin = 24.99% ((Revenue TTM 22.35b - Cost of Revenue TTM 16.76b) / Revenue TTM)
Gross Margin QoQ = 23.70% (prev 26.12%)
Tobins Q-Ratio = 0.90 (Enterprise Value 38.12b / Total Assets 42.46b)
Interest Expense / Debt = 0.63% (Interest Expense 86.0m / Debt 13.58b)
Taxrate = 24.22% (116.0m / 479.0m)
NOPAT = 1.30b (EBIT 1.72b * (1 - 24.22%))
Current Ratio = 1.26 (Total Current Assets 12.06b / Total Current Liabilities 9.56b)
Debt / Equity = 0.73 (Debt 13.58b / totalStockholderEquity, last quarter 18.62b)
Debt / EBITDA = 4.48 (Net Debt 11.53b / EBITDA 2.57b)
Debt / FCF = 15.46 (Net Debt 11.53b / FCF TTM 746.0m)
Total Stockholder Equity = 18.96b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.69% (Net Income 1.14b / Total Assets 42.46b)
RoE = 6.03% (Net Income TTM 1.14b / Total Stockholder Equity 18.96b)
RoCE = 6.02% (EBIT 1.72b / Capital Employed (Equity 18.96b + L.T.Debt 9.53b))
RoIC = 4.20% (NOPAT 1.30b / Invested Capital 30.95b)
WACC = 4.23% (E(26.91b)/V(40.49b) * Re(6.12%) + D(13.58b)/V(40.49b) * Rd(0.63%) * (1-Tc(0.24)))
Discount Rate = 6.12% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 76.54% ; FCFE base≈1.42b ; Y1≈1.27b ; Y5≈1.08b
Fair Price DCF = 34.64 (DCF Value 19.51b / Shares Outstanding 563.2m; 5y FCF grow -13.08% → 3.0% )
EPS Correlation: 20.02 | EPS CAGR: -3.58% | SUE: 0.39 | # QB: 0
Revenue Correlation: -84.91 | Revenue CAGR: -14.72% | SUE: -0.10 | # QB: 0
EPS next Year (2026-12-31): EPS=3.70 | Chg30d=-0.018 | Revisions Net=-3 | Growth EPS=+10.6% | Growth Revenue=+5.3%

Additional Sources for FRE Stock

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle